Cancer Chemotherapy and Pharmacology

Papers
(The H4-Index of Cancer Chemotherapy and Pharmacology is 19. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)
ArticleCitations
Tumor microenvironment promotes breast cancer chemoresistance135
Disulfiram: a novel repurposed drug for cancer therapy71
Involvement of cytochrome P450 enzymes in inflammation and cancer: a review54
Cytotoxic mechanisms of doxorubicin at clinically relevant concentrations in breast cancer cells54
Artemisinin-type drugs for the treatment of hematological malignancies36
Exosomal miR-1246 and miR-155 as predictive and prognostic biomarkers for trastuzumab-based therapy resistance in HER2-positive breast cancer36
Reactive oxygen species in cancer: a paradox between pro- and anti-tumour activities32
Aloin alleviates doxorubicin-induced cardiotoxicity in rats by abrogating oxidative stress and pro-inflammatory cytokines28
Anticancer effects of brusatol in nasopharyngeal carcinoma through suppression of the Akt/mTOR signaling pathway26
Honokiol antagonizes doxorubicin resistance in human breast cancer via miR-188-5p/FBXW7/c-Myc pathway25
The role of the glutamine transporter ASCT2 in antineoplastic therapy24
The prognostic value of CA19-9 response after neoadjuvant therapy in patients with pancreatic cancer: a systematic review and pooled analysis24
Berberine chloride suppresses non-small cell lung cancer by deregulating Sin3A/TOP2B pathway in vitro and in vivo24
Safety, tolerability and pharmacokinetics of crizotinib in combination with cytotoxic chemotherapy for pediatric patients with refractory solid tumors or anaplastic large cell lymphoma (ALCL): a Child23
Phase I study of JAK1/2 inhibitor ruxolitinib with weekly paclitaxel for the treatment of HER2-negative metastatic breast cancer20
Dose adjustment of venetoclax when co-administered with posaconazole: clinical drug–drug interaction predictions using a PBPK approach20
EVs delivery of miR-1915-3p improves the chemotherapeutic efficacy of oxaliplatin in colorectal cancer20
Irinotecan-induced intestinal mucositis in mice: a histopathological study20
Niraparib with androgen receptor-axis-targeted therapy in patients with metastatic castration-resistant prostate cancer: safety and pharmacokinetic results from a phase 1b study (BEDIVERE)19
0.042519092559814